Lynch, Amy I <br/><br/>
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.  [electronic resource] 

 -  Pharmacogenetics and genomics  Jun 2009 
 - 415-21 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1744-6872 
<br/><br/><label>Standard No.: </label>10.1097/FPC.0b013e32832a8e81  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Amlodipine--therapeutic use<br/>Angiotensin-Converting Enzyme Inhibitors--therapeutic use<br/>Antihypertensive Agents--therapeutic use<br/>Calcium Channel Blockers--therapeutic use<br/>Chlorthalidone--therapeutic use<br/>Coronary Disease--genetics<br/>Diuretics--therapeutic use<br/>Fibrinogen--genetics<br/>Genetic Variation<br/>Genotype<br/>Humans<br/>Hypertension--drug therapy<br/>Kidney Failure, Chronic--genetics<br/>Lisinopril--therapeutic use<br/>Middle Aged<br/>Stroke--complications<br/>Treatment Outcome